Covid: WHO classifies Eris as 'variant of interest'

The World Health Organisation (WHO) has classified the EG.5 strain of the SARS-CoV-2 virus circulating in different parts of the world, including India, as a 'variant of interest' but said it did......

India's first nasal Covid vax to be launched on Jan 26

Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company's chairman and managing director Krishna Ella......

COVID: 'India is safe for the present'

'Viral infections rise in winter and better care needs to be taken in the next few months.' IMAGE: A resident receives a nasal spray vaccine as a second booster dose against COVID-19 in Beijing.......

China authorises CoronaVac vaccine for 3-17 yr olds

China has authorised the emergency use of CoronaVac, a COVID-19 vaccine manufactured by Chinese firm Sinovac, for children aged between 3 and 17 years, Sinovac Chairman Yin Weidong said. "But when......

Why India's healthcare system is near collapse today

An analysis of Budget speeches made by finance ministers over 75 years also offers a glimpse of how low on the priority list healthcare has featured for the political class and policy-makers, which......

What's behind Bharat Biotech's Zika 'hype'?

Bharat Biotech started work on developing a vaccine against Zika way back in 2014, but the timing of its announcement has created a flutter in the market. When Bharat Biotech recently......

Serum launches tetanus-diphtheria vaccine

Serum Institute of India has introduced the country's first indigenous tetanus and diphtheria combination vaccine - Td-Vac for adults in the domestic market.This combination vaccine for combating......

Hepatitis vaccine proves a bitter business

The Hepatitis-B vaccine market, which is shared by more than 13 players, has not grown beyond Rs 120 crore (Rs 1.2 billion) against the projected Rs 600 crore (Rs 6 billion) by 2004-05.Retail......